HR
DSGN icon

Howe & Rusling’s Design Therapeutics DSGN Stock Holding History

Howe & Rusling’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-70
Closed -$1K – 524
2022
Q3 		$1K Buy
70
+26
+59% +$517 ﹤0.01% 952
2022
Q2 		$1K Buy
+44
New +$594 ﹤0.01% 942

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Howe & Rusling's DSGN Position: Q4 2022 in Review

Howe & Rusling sold out of Design Therapeutics (DSGN) in Q4 2022, closing a stake of 70 shares — an estimated $1K sold.

Howe & Rusling first reported a position in DSGN in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 83 funds tracked by Wall St. Rank hold DSGN as of Q4 2022.

  • Howe & Rusling reported no remaining Design Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 70 Design Therapeutics shares in Q4 2022, an estimated $1K.
  • Howe & Rusling first reported a position in Design Therapeutics in Q2 2022 and held it in 2 quarters.
  • Howe & Rusling's Design Therapeutics position peaked at $1K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.